Public Hospital Network of Paris (Assistance Publique Hôpitaux de Paris) has Selected Bruker´s IVD MALDI Biotyper for MALDI...
December 02 2010 - 12:00AM
Business Wire
At the 30th Reunion Interdisciplinaire de Chimothérapie
Anti-Infectieuse (RICAI), Bruker announces that the Assistance
Publique Hôpitaux de Paris (APHP) has selected Bruker´s IVD
MALDI Biotyper as their exclusive MALDI-TOF mass spectrometry-based
microbial identification tool. APHP is the association of all 44
public hospitals in Paris, and is the largest public health network
in France. The APHP is providing medical service for the complete
metropolitan area of Paris with more than ten million
inhabitants.
As an immediate result of this selection, the three Hospitals
Bichat, Cochin and Lariboisière have each already ordered an IVD
MALDI Biotyper system. Additionally, the Hospitals Necker and
Pitié-Salpétrière had previously selected and have already been
working with Bruker´s MALDI-TOF mass spectrometers for several
years. The APHP hospitals will use the IVD MALDI Biotyper for mass
spectrometry-based identification of microorganisms, such as
gram-negative bacteria, gram-positive bacteria and yeasts. Due to
typically much faster time-to-result (TTR) and lower consumables
cost, MALDI Biotyper-based microbial identification is currently
more and more replacing classical biochemical identification
approaches. In fact, MALDI Biotyper molecular identification is
almost as specific as sequence-based ‘gold standard’
identification, and allows the rapid identification of most
bacterial species within minutes.
Dr. Martin Rottman, Associate Professor of Microbiology at
University of Versailles and Hospital Raymond Poincaré, Garches
pointed out: “We want to use MALDI-TOF mass spectrometry
identification in routine clinical microbiology applications to
achieve the precision in bacterial identification that could
otherwise only be obtained using time-consuming sequence based
identification. Indeed the currently available biochemical methods
fail to identify many micro-organisms involved in bone and joint
infections. The setup of the ISMABIOs regional network for the
surveillance and treatment of bone and joint infection, jointly
funded by the Region Ile de France through the DIM Malinf program
and AP-HP, the hospital of Versailles and the hospital Croix Saint
Simon will use MALDI-TOF based bacterial identification to achieve
rapid and exact microbial identification in this demanding task.
Bruker’s MALDI Biotyper was selected as an obvious choice because
it is the only platform with CE-IVD marking and the only system
currently validated for clinical use in Europe. Moreover, the
instrument can be connected to the laboratory information system
for defined IVD applications, as well as be used as an open,
research oriented, development platform.”
Mr. Peio Mogabure, Microbiology Business Development Manager at
Bruker Daltonique S.A., added: “Our selection by the APHP hospital
association is a major milestone for further establishing the IVD
MALDI Biotyper as the standard mass spectrometry tool in routine
laboratories for microbial identification in France. During the
last two years, we have successfully implemented the technology at
several university hospitals. With this selection, our market
leading position for MALDI-TOF mass spectrometry based microbial
identification is further underpinned.”
About the Bruker MALDI Biotyper
Bruker’s proprietary MALDI Biotyper solution enables molecular
identification, taxonomical classification or dereplication of
microorganisms like bacteria, yeasts and fungi. Classification and
identification of microorganisms is achieved reliably and quickly
using proteomic fingerprinting by high-throughput
MALDI-TOF mass spectrometry. Applications include clinical
routine microbial identification, environmental and pharmaceutical
analysis, taxonomical research, food and consumer product
processing and quality control, as well as marine microbiology.
Bruker’s robust MALDI Biotyper method requires minimal sample
preparation efforts and offers low consumables cost per sample. The
MALDI Biotyper is available in a research-use-only version, as well
as in an IVD-CE version according to EU directive EC/98/79 in
certain European countries. For more information, please visit
www.maldibiotyper.com.
ABOUT BRUKER
For more information about Bruker Daltonics and Bruker
Corporation (NASDAQ: BRKR), please visit www.bdal.com and
www.bruker.com.
CAUTIONARY STATEMENT OF BRUKER
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995. Any forward-looking statements contained herein are
based on current expectations, but are subject to a number of risks
and uncertainties. The factors that could cause actual future
results to differ materially from current expectations include, but
are not limited to, risks and uncertainties relating to adverse
changes in conditions in the global economy and volatility in the
capital markets, the integration of businesses we have acquired or
may acquire in the future, changing technologies, product
development and market acceptance of our products, the cost and
pricing of our products, manufacturing, competition, dependence on
collaborative partners and key suppliers, capital spending and
government funding policies, changes in governmental regulations,
intellectual property rights, litigation, and exposure to foreign
currency fluctuations. These and other factors are identified and
described in more detail in our filings with the SEC, including,
without limitation, our annual report on Form 10-K for the year
ended December 31, 2009, our most recent quarterly reports on Form
10-Q and our current reports on Form 8-K. We disclaim any intent or
obligation to update these forward-looking statements other than as
required by law.
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024